Linzess is not currently available in a generic version. However, patents related to the drug are set to expire in the coming years, which will likely pave the way for generic alternatives to become available.
When Does Linzess Patent Exclusivity Expire?
The patents protecting Linzess are scheduled to expire at different times. For instance, some patents are slated to end around 2030 [1]. This timeline is crucial for understanding when generic manufacturers could potentially enter the market.
Can Biosimilars Be Developed Before Patent Expiry?
Generally, biosimilar development and approval processes are closely tied to patent expiry. The expiration of patents for Linzess would allow for the development and marketing of generic versions of the medication [1].
What Companies Are Involved with Linzess?
Linzess is jointly developed and marketed by Ironwood Pharmaceuticals and AbbVie [2]. Understanding the manufacturers is key when looking for information on drug availability and potential competition.
What Are the Alternatives to Linzess?
For individuals seeking treatment for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), other medications are available. These might include drugs like Amitiza, Trulance, or Constella, though their mechanisms of action and efficacy can differ [3]. The availability of generic options for Linzess could introduce new cost-effective choices in the future.